For patients facing joint-replacement surgery, or told "there's nothing more to do," MSC therapy is a precision-delivered, image-guided alternative. It works with the body's own repair machinery, not around it.
Not every joint complaint is a candidate for cell therapy. We group by anatomical region and screen each indication against the evidence, your imaging, and your goals.
Our most-screened region. Image-guided intra-articular injection delivers MSCs directly to the joint space.
Fluoroscopic guidance places cells precisely at the femoral head–acetabular interface.
Ultrasound-guided delivery to glenohumeral joint, rotator cuff tendon, or AC joint as indicated.
Image-guided facet or epidural delivery. Disc therapy is case-by-case, with strict imaging screening.
We turn down a significant share of inquiries. Not because we can't help. Because MSC therapy isn't the right tool for every problem. Here is the honest screen.
The general Celva methodology has five stages. For joint indications, here are the numbers that differ: dosing, route, session count, and what pre- and post-care look like.
MRI and weight-bearing X-ray read by our attending. CBC, CMP, inflammatory markers, and coagulation panel within 14 days of procedure.
Target joint is prepped under sterile technique. Cells are drawn into a 5cc syringe and injected under live fluoroscopic or ultrasound guidance. Position confirmed before release.
A second allogeneic MSC dose is delivered IV in the infusion suite: 45 minutes, monitored. Joint delivery addresses the target. IV addresses systemic inflammation.
Short observation. Discharge instructions. Concierge transport back to San Diego. You are walking the same day.
Scheduled virtual visits at 30, 60, and 90 days. Pain-function scales (KOOS / HOOS / SPADI) and imaging re-read at 6 months.
Aggregated from the Celva joint registry. Pain reduction is measured on the standardized VAS and KOOS/HOOS/SPADI scales at 6 months. Individual results vary; we measure and report both.
***NoteOutcome figures are placeholder values for design purposes. Final site will display registry-verified numbers updated quarterly.
De-identified, consent-verified cases from the Celva registry. Chosen to represent typical trajectories, not only the best outcomes.
Patient was scheduled for a total knee arthroplasty after two years of conservative care and a corticosteroid course. Bilateral MRI showed Grade III chondral loss, medial compartment. Treated with image-guided intra-articular MSC plus systemic IV. Six-month re-image showed no further progression and KOOS function up from 42 to 76.
Masters-level swimmer with a supraspinatus partial tear and refractory tendinopathy after PT and one PRP course. Ultrasound-guided MSC injection to tendon and bursa, plus systemic IV. Returned to full-yardage training at week 10 with no recurrence through one-year follow-up.
All-in. Concierge transport + procedure + IV adjunct + follow-up.
Range reflects joint (knee vs. hip vs. spine), delivery complexity (single-region vs. bilateral), and whether an add-on IV dose is indicated. Bilateral and multi-region protocols are priced at the consult, not per-visit.
We do not take insurance. Cell therapy is not yet covered in the United States. We publish clear numbers so you can decide before you book a consult.
See full pricing matrix →For patients who want the detailed story on a specific joint, the alternatives they've already tried, or the recovery timeline. One page per topic.
Send us your imaging, tell us about your joint, and we'll tell you plainly whether MSC therapy is the right next step. If it isn't, we'll say so.